Published in Sci Rep on August 07, 2017
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J (2001) 3.80
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe (2008) 2.81
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med (2014) 2.76
Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc (2008) 2.34
Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol (2000) 2.30
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest (2000) 2.21
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog (2013) 2.16
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis (2002) 1.91
HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis (2014) 1.89
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog (2014) 1.88
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem (2012) 1.85
Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc (2008) 1.76
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest (2015) 1.76
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. J Am Chem Soc (2008) 1.64
Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog (2014) 1.59
Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des (2008) 1.59
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem (2011) 1.45
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35
Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res (2010) 1.25
Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci U S A (2013) 1.24
A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One (2012) 1.23
Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol (2003) 1.15
Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J Pharmacol Exp Ther (2010) 1.13
HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Res Hum Retroviruses (2006) 1.12
Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res Hum Retroviruses (2004) 1.10
Tat acetyl-acceptor lysines are important for human immunodeficiency virus type-1 replication. J Biol Chem (2002) 1.07
Synthesis and activity of largazole analogues with linker and macrocycle modification. Org Lett (2008) 1.07
A New Bliss Independence Model to Analyze Drug Combination Data. J Biomol Screen (2014) 1.05
Largazole: from discovery to broad-spectrum therapy. Nat Prod Rep (2012) 1.03
Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol (1998) 1.00
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res (2000) 0.98
The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4+ T Cells. J Infect Dis (2015) 0.97
Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc Natl Acad Sci U S A (2014) 0.97
Rational design of drugs that induce human immunodeficiency virus replication. J Virol (2003) 0.93
Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation. Biochem Pharmacol (2007) 0.93
Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One (2014) 0.92
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS (2016) 0.88
Epigenetic regulation of HIV-1 transcription. Epigenomics (2011) 0.83
Histone deacetylase inhibitors: structure-based modeling and isoform-selectivity prediction. J Chem Inf Model (2012) 0.81
Largazole pharmacokinetics in rats by LC-MS/MS. Mar Drugs (2014) 0.78
The effect of N-acetylation and N-methylation of lysine residue of Tat peptide on its interaction with HIV-1 TAR RNA. PLoS One (2013) 0.78
Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors. J Med Chem (2016) 0.76
Electron Decoupling with Dynamic Nuclear Polarization in Rotating Solids. J Am Chem Soc (2017) 0.75